SG Americas Securities LLC lessened its holdings in LivaNova PLC (NASDAQ:LIVN – Free Report) by 78.1% during the third quarter, HoldingsChannel.com reports. The firm owned 2,844 shares of the company’s stock after selling 10,113 shares during the period. SG Americas Securities LLC’s holdings in LivaNova were worth $149,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Hexagon Capital Partners LLC increased its stake in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares during the last quarter. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after acquiring an additional 332 shares in the last quarter. Lazard Asset Management LLC acquired a new position in LivaNova during the first quarter valued at approximately $84,000. Canada Pension Plan Investment Board bought a new position in LivaNova in the second quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC acquired a new position in shares of LivaNova during the 1st quarter worth approximately $94,000. Institutional investors and hedge funds own 97.64% of the company’s stock.
LivaNova Stock Performance
Shares of LIVN stock opened at $53.00 on Friday. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -88.33 and a beta of 1.00. The company has a 50-day simple moving average of $50.40 and a 200 day simple moving average of $53.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45.
Analysts Set New Price Targets
LIVN has been the subject of several recent analyst reports. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $55.00 to $66.00 in a report on Tuesday, September 17th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Needham & Company LLC boosted their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Stifel Nicolaus upped their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $69.83.
Read Our Latest Research Report on LIVN
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Recommended Stories
- Five stocks we like better than LivaNova
- What is the Australian Securities Exchange (ASX)
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Dividend Challengers?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Buy P&G Now, Before It Sets A New All-Time High
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN – Free Report).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.